In the landscape of modern medicine, few challenges are as persistent or as emotionally taxing as the “diagnostic odyssey”—a years-long journey during which patients, often children, navigate a labyrinth of specialists, inconclusive tests, and mounting medical bills in search of a name for their rare genetic condition. A recent study published in Human Genetics and Genomics Advances (HGGA) titled, “Exome sequencing early in outpatient evaluation in NCGENES 2: Changing the course of the diagnostic odyssey?” suggests that the integration of early-stage exome sequencing (ES) could fundamentally shorten this journey.
We sat down with the study’s lead researcher, Dr. Tamara Roman, a Variant Analyst at UNC Health, to explore how this approach is not just a technological upgrade, but a paradigm shift in how clinicians approach undiagnosed diseases.
The Core Challenge: Why the Odyssey Persists
The diagnostic odyssey is a phenomenon characterized by a lack of clarity. For families dealing with rare, suspected genetic disorders, the path to a definitive diagnosis can take upwards of five to seven years. During this time, patients often undergo redundant testing, invasive procedures, and prolonged uncertainty.
The traditional clinical model often reserves genomic sequencing as a “last resort” once standard workups—such as metabolic panels, imaging, and karyotyping—have failed to yield results. However, as Dr. Roman points out, the delay itself causes significant psychological and financial strain. The NCGENES 2 study aimed to test a bold hypothesis: What happens when you flip the script and place exome sequencing at the beginning of the outpatient evaluation?
Defining the Diagnostic Odyssey
The term refers to the cumulative time and effort spent by a patient searching for a diagnosis for a complex, often multi-system condition. In many cases, these conditions are caused by rare variants that are invisible to traditional diagnostic tools. By the time a patient reaches a specialized genetic center, they have often exhausted their emotional and financial resources.
Chronology of the NCGENES 2 Initiative
The NCGENES 2 project was built on the foundation of earlier clinical research designed to evaluate the utility of genomic medicine in real-world settings.
- Phase I: Conceptualization and Interdisciplinary Assembly: The project began with the assembly of a diverse team. Recognizing that genomic medicine is inherently multi-disciplinary, the team brought together clinical geneticists, laboratory geneticists, genetic counselors, research faculty, and students.
- Phase II: Clinical Integration: Rather than sequestering the research in a lab, the team integrated the testing process directly into the standard outpatient workflow at UNC Health. The goal was to observe how clinicians interacted with genomic data in real-time.
- Phase III: Data Accumulation and Analysis: Over the course of the study, the team performed exome sequencing on a cohort of patients. They focused not only on the raw diagnostic yield but on the “actionability” of the results—how quickly a diagnosis could be confirmed and how that information altered the patient’s management plan.
- Phase IV: Post-Analytical Reclassification: A significant portion of the work involved the ongoing analysis of Variants of Uncertain Significance (VUS). As the team gathered more longitudinal data, they began the process of re-evaluating these variants, proving that a negative result at month one does not have to be a negative result forever.
Supporting Data: The Impact of Early Sequencing
The data gathered during the NCGENES 2 study reinforces the argument for "front-loading" genetic diagnostics. While the final report details the technical success rates of exome sequencing, the qualitative data regarding the patient experience is equally compelling.
Variant Classification and the "VUS" Hurdle
One of the primary roadblocks in clinical genomics is the Variant of Uncertain Significance. When a sequencing report comes back, it is rarely a simple "yes" or "no." Often, it identifies a variant that might be pathogenic but lacks sufficient supporting evidence.
“These VUS can be challenging to interpret in the context of limited data,” Dr. Roman explains. “This highlights the importance of periodically evaluating emerging data to potentially reclassify variants.” The study emphasizes that the clinical utility of an exome test does not end when the report is filed. Instead, it requires a continuous feedback loop where researchers and clinicians monitor global databases to see if new functional studies or population data can finally classify a VUS as benign or pathogenic.
The Multi-Disciplinary Advantage
The project’s success was attributed heavily to its collaborative structure. By including students and various clinical staff, the study fostered an environment where the “translation” of genetic data into clinical practice was streamlined. Laboratory geneticists provided the technical precision, while genetic counselors ensured that the families understood the implications of the findings, bridging the gap between cold, hard data and human reality.
Expert Perspective: Dr. Tamara Roman on the Future of Genomics
Dr. Roman’s journey into this research was driven by a fundamental curiosity about the clinical utility of genomic information. As a Variant Analyst, she sits at the intersection of bioinformatic data and patient care.
Overcoming the "Young Scientist" Barrier
When asked about the challenges of working in such a fast-paced environment, Dr. Roman is candid. "The field of genetics is rapidly evolving," she notes. "It can be challenging to stay updated and familiar with novel technologies and increased data."
The sheer volume of new literature, combined with the rapid pace of technological innovation, requires a constant commitment to learning. For early-career scientists, the pressure to not only contribute to the field but to keep pace with it is immense. Yet, Dr. Roman finds the work inherently rewarding. Her enthusiasm for the collaborative nature of the NCGENES 2 study suggests that the future of the field lies in breaking down the silos between the bench and the bedside.
Fascinating Frontiers: Beyond Human Genetics
Even outside her own research, Dr. Roman is keenly observant of the broader implications of genetic engineering. When asked about the most fascinating development in the field over the last year, she pointed toward a surprising area: heritable immunization in mice.
The work of Dr. Kevin Esvelt regarding the use of CRISPR-based genetic engineering to create mice capable of inheriting resistance to Lyme disease has captured the imagination of the scientific community. By engineering mice to express a monoclonal antibody against the bacteria that causes Lyme, researchers are exploring how genetic modifications can ripple through an ecosystem. While this is a far cry from human diagnostics, it highlights the increasing power of genomic manipulation to solve complex public health crises.
Implications for the Future of Clinical Practice
The implications of the NCGENES 2 study for the human genetics community are profound. If early exome sequencing becomes the standard of care, we could see a drastic reduction in the duration of the diagnostic odyssey.
1. Shift in Insurance and Policy Models
The study provides the evidence base needed to advocate for earlier coverage of exome sequencing. Currently, many insurance providers demand that standard diagnostics be exhausted before approving expensive sequencing. The data from NCGENES 2 suggests that if we wait, we may actually be increasing costs by prolonging the search for a diagnosis.
2. The Living Report
The study underscores the necessity of "living" electronic health records (EHRs) that automatically alert clinicians when a previously classified VUS is updated in a global database. The "periodic evaluation" mentioned by Dr. Roman is not just a research task; it should be a clinical requirement.
3. Education and Training
As genomics moves into the primary care setting, there is a growing need for genetic literacy among general practitioners. The collaborative model used in the study—where specialists and generalists worked together—provides a blueprint for how this knowledge transfer can occur in hospitals and clinics worldwide.
Conclusion
The work of Dr. Tamara Roman and the NCGENES 2 team serves as a vital reminder that genomic medicine is ultimately a human endeavor. By treating the diagnostic odyssey not as an inevitable reality of rare disease, but as a clinical inefficiency to be solved, the medical community is moving closer to a future where answers come sooner.
As we look ahead, the challenge will be scaling these findings. How do we ensure that every clinic, regardless of size, has the tools and the expertise to interpret these complex results? The answer, as the study suggests, lies in continued collaboration, a dedication to long-term variant monitoring, and a refusal to accept the status quo of the diagnostic journey. The odyssey may not be over, but thanks to the insights from researchers like Dr. Roman, the path forward is finally becoming clear.
About the Author
